SecBot SecBot
DEF 14A ·Filed Nov 2, 2026

CRIS

CURIS INC
NEUTRAL
Impact 4/10
Horizondays Processed14d 19h ago SEC0001140361-26-041419
Definitive proxy statement
Actionable Insight • Neutral

Monitor the shareholder vote outcome on November 18, 2026. If approved, the board has six months to implement the reverse split at a ratio of its choosing. The company's ability to maintain Nasdaq listing is critical given its $4M market cap and history of non-compliance.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$0.6610
T+0 close · Nov 2, 2026 · via day close
Latest settled
+5.54%
T+5 · $0.6976 · next T+20 in 14d
Vs SPY
+5.46%
α at T+5
Latest observation
−27.03%
T+10 · FF3 residual α
  1. T+0 · Nov 2 $0.6610entry
  2. T+1 · 14d ago +8.00%α +7.70% · $0.7139
  3. T+5 · 8d ago +5.54%α +5.46% · $0.6976
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Curis Inc. is holding a special shareholder meeting on November 18, 2026 to vote on two proposals: (1) authorizing a reverse stock split at a ratio between 1-for-5 and 1-for-12 to regain compliance with Nasdaq's minimum bid price requirement, and (2) adjourning the meeting if necessary to solicit additional votes. The company has a market cap of only $4M and has been at risk of delisting, having received a delist determination letter in April 2026 before regaining compliance in July 2026. The filing is a routine proxy solicitation for a reverse split authorization, which is a defensive measure to maintain listing.

Key Facts

  • Special meeting scheduled for November 18, 2026 to vote on reverse stock split (ratio range 1-for-5 to 1-for-12) and adjournment proposal.
  • As of October 20, 2026, there were 6,679,229 shares of common stock outstanding.
  • Company received a Delist Determination Letter from Nasdaq on April 27, 2026 for non-compliance with the $1.00 bid price rule, but regained compliance on July 24, 2026 and is under a Discretionary Panel Monitor until July 24, 2027.
  • Board of directors recommends voting FOR both proposals.
  • No executive compensation, director elections, shareholder proposals, or related party transactions are being voted on at this special meeting.
  • Four 5% stockholders: Bleichroeder LP (9.99%), Stonepine Capital LP (9.99%), Pointillist Partners LLC (8.24%), and entities affiliated with Thomas A. Satterfield, Jr. (6.39%).

Financial Impact

No financial data provided in the filing. The reverse stock split would reduce outstanding shares from 6,679,229 to between 1,335,846 (1-for-5) and 556,603 (1-for-12).

share countstock price

Risk Factors

  • Reverse stock split may not permanently increase stock price above $1.00 or maintain Nasdaq compliance.
  • Reduced share count could decrease liquidity and result in odd-lot holdings.
  • Company has a history of Nasdaq non-compliance and remains under a Discretionary Panel Monitor until July 2027.
  • Significant warrant overhang exists, with pre-funded warrants for 15,964,140 shares and common warrants for 23,782,339 shares outstanding as of October 20, 2026.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEF 14A Filing (Primary)0001140361-26-041419
Document: 0001140361-26-041419-index-headers.html0001140361-26-041419
Document: 0001140361-26-041419-index.html0001140361-26-041419
Document: 0001140361-26-041419.txt0001140361-26-041419

Track record

18 reports on CRIS

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +82.45% at T+60 after the May 22, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.4200 Now $0.4400 +4.76% settles Nov 17
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.6000 Now $0.4400 −26.67% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.5010 Now $0.4400 −12.18% settles Nov 17
  4. Nov 13, 20263d ago S-3 Bearish 7/10 Entry $0.6000 Now $0.4400 +26.67% settles Nov 17
  5. Nov 13, 20263d ago 8-K Neutral 4/10 Entry $0.4450 Now $0.4400 −1.12% settles Nov 17
  6. Nov 12, 20264d ago Press Release Bearish 6/10 Entry $0.4450 to $0.4358 Now $0.4400 +1.12% ▲ +2.07% +0.16% vs SPY
  7. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $0.6530 to $0.5915 Now $0.4400 −32.62% ▼ −9.42% −10.74% vs SPY
  8. Nov 6, 202610d ago 8-K Bearish 7/10 Entry $0.6976 to $0.6530 Now $0.4400 +36.93% ▲ +6.39% +6.03% vs SPY
  9. Nov 2, 202614d ago DEF 14A Neutral 4/10 Viewing Entry $0.6610 to $0.7139 Now $0.4400 −33.43% ▲ +8.00% +7.70% vs SPY
  10. Oct 19, 202628d ago 8-K Bearish 6/10 Entry $0.3996 to $0.3920 Now $0.4400 −10.11% ▲ +1.90% +2.43% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026